Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Autoimmunity. 2014 Nov 20;48(4):222–230. doi: 10.3109/08916934.2014.984836

Figure 4.

Figure 4

Acthar dampens astrogliosis in the spinal cords of EAE mice. (A) Representative spinal cord tissue sections stained for GFAP, as described in the “Methods” section. Images shown at 20× magnification and insets at 10× magnification. (B) Quantification of GFAP scoring (described in the “Methods” section) of spinal cord tissue sections obtained from mice in which treatment was initiated at the onset of relapse (n = 15 for no treatment, 12 for Acthar treatment and 10 for Placebo gel treatment). *p<0.05, one-way ANOVA followed by Dunn’s test. (C) Quantification of GFAP scoring of spinal cord sections obtained from mice in which treatment was initiated after the onset of relapse (n = 16 for all groups of mice). **p<0.01, ANOVA followed by Holm–Sidak test. Values represent the mean ± SEM (at least six spinal cord tissue sections were scored for each mouse). NT no treatment.